Publications by authors named "Beat Helbling"

Claim this Profile
G
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland.
Benedetta Terziroli Beretta-Piccoli, Guido Stirnimann, Andreas Cerny, David Semela, Roxane Hessler, Beat Helbling

Clin Rev Allergy Immunol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1.
Felix Stickel, Mathias Worni, Isabelle Pache, Darius Moradpour, Beat Helbling

Am J Gastroenterol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Jean-François Dufour, Hanno Hoppe, Markus H Heim, Beat Helbling, Olivier Maurhofer

Oncologist· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Hepatitis C virus infection in Swiss primary care practices: low case loads-high barriers to treatment?
Kathrin Overbeck, Philip Bruggmann, Beat Helbling

Eur J Gen Pract· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C.
Caroline Hora, Francesco Negro, Giacchino Leandro, Carl M Oneta, Laura Rubbia-Brandt, Beat Helbling

Liver Int· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS).
Leonie Prasad, Virginie Masserey Spicher, Marcel Zwahlen, Martin Rickenbach, Beat Helbling

Int J Epidemiol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
Jean-François Dufour, Carl M Oneta, Jean-Jacques Gonvers, Florian Bihl, Andreas Cerny, Beat Helbling

Clin Gastroenterol Hepatol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.
Beat Helbling, Wolfram Jochum, Ivan Stamenic, Marina Knöpfli, Andreas Cerny

J Viral Hepat· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C.
Barbara Broers, Beat Helbling, Anne François, Patrick Schmid, Christian Chuard

J Hepatol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients.
Alba Muzzi, Gioacchino Leandro, Laura Rubbia-Brandt, Richard James, Olivia Keiser, Beat Helbling

J Hepatol· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials.
Alessandra Mangia, Gioacchino Leandro, Beat Helbling, Eberhard L Renner, Marco Tabone

J Hepatol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial.
Beat Helbling, Ivan Stamenic, Francesco Viani, Jean-Jacques Gonvers, Jean-Francois Dufour

Hepatology· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis